The W9 peptide directly stimulates osteoblast differentiation via RANKL signaling

Journal of Oral Biosciences

Volumn 59, Issue 3, 2017, Pages 146-151

  Nakamura, Midori ^a   Nakamichi, Yuko ^a   Mizoguchi, Toshihide ^a   Koide, Masanori ^a   Yamashita, Teruhito ^a   Ara, Toshiaki ^a   Nakamura, Hiroshi ^a   Penninger, Josef M ^b   Furuya, Yuriko ^c   Yasuda, Hisataka ^c   Udagawa, Nobuyuki ^a  

^a MATSUMOTO DENTAL UNIVERSITY   (Japan)

^b INSTITUTE OF MOLECULAR BIOTECHNOLOGY   (Austria)

^c Oriental Yeast Co Ltd   (Japan)

Author keywords

Bone formation; Osteoblast; Osteoclast; RANKL; W9 peptide

Indexed keywords

EID: 85019753777     PISSN: 13490079     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.job.2017.05.001     Document Type: Article

References (29)

1. Rodan, G.A., Martin, T.J., Role of osteoblasts in hormonal control of bone resorption – a hypothesis. Calcif Tissue Int 33 (1981), 349–351.
2. Teitelbaum, S.L., Ross, F.P., Genetic regulation of osteoclast development and function. Nat Rev Genet 4 (2003), 638–649.
3. Roodman, G.D., Regulation of osteoclast differentiation. Ann N Y Acid Sci 1068 (2006), 100–109.
4. Chambers, T.J., The birth of the osteoclast. Ann N Y Acid Sci 1192 (2010), 19–26.
5. Udagawa, N., Takahashi, N., Akatsu, T., Tanaka, H., Sasaki, T., Nishihara, T., et al. Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells. Proc Natl Acid Sci USA 87 (1990), 7260–7264.
6. Takahashi, N., Akatsu, T., Udagawa, N., Sasaki, T., Yamaguchi, A., Jane, M.M., et al. Osteoblastic cells are involved in osteoclast formation. Endocrinology 123 (1987), 2600–2602.
7. Yoshida, H., Hayashi, S., Kunisada, T., Ogawa, M., Nishikawa, S., Okamura, H., et al. The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature 345 (1990), 442–444.
8. Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S., et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acid Sci USA 95 (1990), 3597–3602.
9. Suda, T., Takahashi, N., Udagawa, N., Jimi, E., Gillespie, M.T., Martin, T.J., Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 20 (1990), 345–357.
10. Simonet, W.S., Lacey, D.L., Dunstan, C.R., Kelley, M., Chang, M.S., Lüthy, R., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89 (1997), 309–319.
11. Yasuda, H., Shima, N., Nakagawa, N., Mochizuki, S.I., Yano, K., Fujise, N., et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139 (1998), 1329–1337.
12. Kong, Y.Y., Yoshida, H., Sarosi, I., Tan, H.L., Timms, E., Capparelli, C., et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397 (1999), 315–323.
13. Dougall, W.C., Glaccum, M., Charrier, K., Rohrbach, K., Brasel, K., De Smedt, T., et al. RANK is essential for osteoclast and lymph node development. Genes Dev 13 (1999), 2412–2424.
14. Bucay, N., Sarosi, I., Dunstan, C.R., Morony, S., Tarpley, J., Capparelli, C., et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12 (1998), 1260–1268.
15. Mizuno, A., Amizuka, N., Irie, K., Murakami, A., Fujise, N., Kanno, T., et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 247 (1998), 610–625.
16. Zebaze RM, Libanati C, McClung MR, Zanchetta JR, Kendler DL, Høiseth A, et al.Denosumab reduces cortical porosity of the proximal femoral shaft in postmenopausal women with osteoporosis. J Bone Miner Res 31, 2016,1827-1834.
17. Furuya, Y., Inagaki, A., Khan, M., Mori, K., Penninger, J.M., Nakamura, M., et al. Stimulation of bone formation in cortical bone of mice treated with a preceptor activator of nuclear factor-κB ligand (RANKL)-binding peptide that possesses osteoclastogenesis inhibitory activity. J Biol Chem 288 (2013), 5562–5571.
18. Takasaki, W., Kajino, Y., Kajino, K., Murali, R., Greene, M.I., Structure-based design and characterization of exocyclic peptidomimetics that inhibit TNF alpha binding to its receptor. Nat Biotechnol 15 (1997), 1266–1270.
19. Aoki, K., Saito, H., Itzstein, C., Ishiguro, M., Shibata, T., Blanque, R., et al. A TNF receptor loop peptide mimic blocks RANK ligand-induced signaling, bone resorption, and bone loss. J Clin Invest 116 (2006), 1525–1534.
20. Sato, N., Takahashi, N., Suda, K., Nakamura, M., Yamaki, M., Ninomiya, T., et al. MyD88 but not TRIF is essential for osteoclastogenesis induced by lipopolysaccharide, diacyl lipopeptide, and IL-1α. J Exp Med 200 (2004), 601–611.
21. Itoh, K., Udagawa, N., Matsuzaki, K., Takami, M., Amano, H., Shinki, T., et al. Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors. J Bone Miner Res 15 (2000), 1766–1775.
22. Koide, M., Kobayashi, Y., Ninomiya, T., Nakamura, M., Yasuda, H., Arai, Y., et al. Osteoprotegerin-deficient male mice as a model for severe alveolar bone loss. Comparison with RANKL-overexpressing transgenic male mice. Endocrinology 154 (2013), 773–782.
23. Nakamura, M., Udagawa, N., Matsuura, S., Mogi, M., Nakamura, H., Horiuchi, H., et al. Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption. Endocrinology 144 (2003), 5441–5449.
24. Udagawa, N., Takahashi, N., Yasuda, H., Mizuno, A., Itoh, K., Ueno, Y., et al. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. Endocrinology 141 (2000), 3478–3484.
25. Yamamoto, Y., Udagawa, N., Matsuura, S., Nakamichi, Y., Horiuchi, H., Hosoya, A., et al. Osteoblasts provide a suitable microenvironment for the action of receptor activator of nuclear factor-κB ligand. Endocrinology 147 (2006), 3366–3374.
26. Khan, A.A.M.K., Alles, N., Soysa, N.S., Nagano, K., Mikami, R., Furuya, Y., et al. The local administration of TNF-α and RANKL antagonist peptide promotes BMP-induced bone formation. J Oral Biosci 55 (2013), 47–54.
27. Mamun, M.A.A., Khan, A.A.M.K., Alles, N., Soysa, N.S., Matsui, M., Tabata, Y., et al. Gelatin hydrogel carrier with the W9-peptide elicits synergistic effects on BMP-2-induced bone regeneration. J Oral Biosci 55 (2013), 217–223.
28. Katagiri, T., Yamaguchi, A., Komaki, M., Abe, E., Takahashi, N., Ikeda, T., et al. Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage. J Cell Biol 127 (1994), 1755–1766.
29. Isogai, Y., Akatsu, T., Ishizuya, T., Yamaguchi, A., Hori, M., Takahashi, N., et al. Parathyroid hormone regulates osteoblast differentiation positively or negatively depending on the differentiation stages. J Bone Miner Res 10 (1996), 1384–1393.